Belimumab - Wikipedia
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis.
Benlysta: What you need to know | Lupus Foundation of America
The objective of this report is to perform a systematic review of the beneficial and harmful effects of belimumab 200 mg/mL subcutaneous injection in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus.
BENLYSTA (belimumab) for Lupus and Lupus Nephritis | HCP Website
Clinical Review Report: Belimumab (Benlysta): (GlaxoSmithKline Inc.): Indication: Indicated in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus [Internet]. Show details
Benlysta Infusion/IV: Uses, Dosage, Side Effects - Drugs.com
Benlysta is a medicine for patients with systemic lupus erythematosus (SLE) and active lupus nephritis. It contains the active substance belimumab, a monoclonal antibody that blocks a protein involved in the immune system. It is given by infusion or injection as an add-on treatment with other immunosuppressants. The European Medicines Agency decided that its benefits are greater than its risks and authorised it for use in the EU.
Benlysta | European Medicines Agency
Benlysta is a biologic drug that can help manage lupus symptoms and prevent organ damage. Learn about its development, approval, side effects, cost, and more from the National Resource Center on Lupus.
Belimumab (Benlysta) for the treatment of systemic lupus erythematosus ...
BENLYSTA is a B-lymphocyte stimulator (BLyS) inhibitor for the treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus. Learn about its dosage, administration, contraindications, warnings, adverse reactions, and more from the official label of the U.S. Food and Drug Administration.
Benlysta: Side effects, uses, cost, dosage, and more - Medical News Today
CLINICAL PARTICULARS. 4.1 Therapeutic indications. Benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy (see section 5.1).
Benlysta: Side Effects, Cost, Uses, and More - Healthline
Abstract. Belimumab (Benlysta ®) is a human immunoglobulin G1λ monoclonal antibody that inhibits the binding of soluble B lymphocyte stimulator to B cells. It is the only biological agent currently approved for the treatment of non-renal systemic lupus erythematosus (SLE).
Clinical Review Report: Belimumab (Benlysta) - NCBI Bookshelf
Benlysta is a biologic drug that contains belimumab and is used to treat lupus in adults and some children. Learn about its side effects, cost, dosage, and how it works.
FDA approves GSK's BENLYSTA as the first medicine for adult patients ...
Benlysta is a monoclonal antibody for treating adult patients with active systemic lupus erythematosus (SLE). Learn about its side effects, interactions, warnings, and how to use it by injection or infusion.